IDEXX Laboratories is a leading provider of veterinary diagnostics and software, headquartered in Westbrook, Maine. The company develops diagnostic products, instruments, and services for the companion animal veterinary market, with additional offerings for livestock, poultry, dairy, and water testing. Its core franchise is the Companion Animal Group, which serves veterinary clinics through in-clinic analyzers, reference laboratory testing, and rapid assay tests.
The company's "razor-and-blade" model is central to its appeal: IDEXX places diagnostic instruments such as the inVue Dx Cellular Analyzer in clinics, then generates ongoing recurring revenue from test consumables, reference lab work, and software. This structure produces a large, predictable base of recurring revenue that grows as clinics run more tests per visit and adopt new assays. Investors follow IDXX closely because of its dominant position in pet diagnostics, its durable revenue mix, and its exposure to long-term trends in pet healthcare spending. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Over the trailing 30 days, IDXX shares rose approximately 33%, advancing from a close near $529 to roughly $704. The bulk of that gain arrived in a single session in early November, when the stock surged about 22% following third-quarter results.
The picture over the trailing three months is more nuanced. Shares began the period near $567 in mid-August, then slid to a closing low near $505 in mid-September amid worries about soft veterinary clinic traffic. From that low, the stock staged a broad recovery that accelerated sharply after earnings, leaving IDXX up roughly 24% over the three-month period. The result is a V-shaped move in which a prolonged decline gave way to a rapid re-rating.
The dominant catalyst was IDEXX's third-quarter 2026 report, released in early November. Revenue rose 10% year over year to about $1.21 billion, ahead of a consensus near $1.19 billion, with the Companion Animal Group leading growth. Reported diluted earnings per share reached $4.01, up 18% from a year earlier, while comparable EPS of $3.96 cleared analyst estimates of roughly $3.71. Net income rose 16% to about $317 million.
Guidance reinforced the positive reaction. IDEXX raised its full-year revenue outlook to a range of $4.741 billion to $4.767 billion and its EPS outlook to $14.96 to $15.16, marking the third increase of the year. The company did trim its operating-margin guidance to 32.1% to 32.3%, citing integration costs tied to the acquisition of CoVet, an AI clinical assistant for veterinary teams.
The move was also about positioning. Before the report, shares had been under pressure because of declining U.S. veterinary clinic visits and, in late October, a price-target cut by a major bank. The strong quarter showed IDEXX could grow diagnostics revenue even with soft clinic traffic, as veterinarians run more tests per visit and adopt new instruments. A broader rotation from technology into healthcare and consumer-related names provided an additional tailwind.
The broader three-month story was one of investor skepticism giving way to renewed confidence. Through September, sentiment was weighed down by a multi-year debate over weak veterinary visit frequency and fears that a companion-animal pricing war could pressure margins. Those concerns drove the stock to its mid-September low.
The November report changed the narrative. Double-digit growth in recurring diagnostics revenue, strong inVue Dx placements, and the CoVet acquisition demonstrated that IDEXX's innovation strategy could offset soft traffic. The quarter also showed operating margin expansion, even while absorbing acquisition costs. This combination — a beat, a guidance raise, and evidence that pricing and testing intensity could outrun weaker foot traffic — underpinned the sharp re-rating late in the period.
Investors should monitor several factors in the months ahead. First is whether U.S. veterinary clinic visit trends stabilize or recover, since sustained weakness would test IDEXX's ability to keep growing through price and testing intensity. Second is the integration of the CoVet AI acquisition and its effect on margins, given that the company trimmed its operating-margin outlook. Third, watch instrument placement momentum for the inVue Dx analyzer and continued adoption of newer tests, which drive future recurring revenue. Finally, competitive dynamics in companion-animal diagnostics and any change in pricing conditions remain key swing factors, along with macroeconomic pressures on discretionary pet spending and currency effects on international results. From what I see, these elements will shape the next moves.
In my analysis of market movements like this one, I often turn to Tickeron’s Trending AI Robots to review how different automated strategies have performed across similar conditions. The section highlights top-performing bots with varying timeframes and approaches, which helps provide additional perspective when evaluating systematic options alongside fundamental research.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial writer and active order flow futures trader with a focus on fundamental analysis, macroeconomic factors, and equity research. I make in-depth blogs on stocks and ETFs, bridging the gap between raw market data and real-world trading decisions.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where IDXX advanced for three days, in 178 of 289 cases, the price rose further within the following month. The odds of a continued upward trend are 62%.
The Momentum Indicator moved above the 0 level on November 02, 2026. You may want to consider a long position or call options on IDXX as a result. In 54 of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 60%.
IDXX moved above its 50-day moving average on October 15, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on October 21, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 8 of 22 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 36%.
The Aroon Indicator entered an Uptrend today. In 97 of 171 cases where IDXX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 57%.
The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
IDXX broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 3 (best 1 - 100 worst), indicating outstanding price growth. IDXX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 65 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 85 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock better than average.
The Tickeron Valuation Rating of 86 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (33.027) is normal, around the industry mean (67.298). P/E Ratio (47.242) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (2.894) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (9.042) is also within normal values, averaging (9.775).
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a manufacturer of animal health products
Industry MedicalSpecialties